AKRO Valuation

Akero Therapeutics Inc

Add to Watchlist

Advanced Chart

54.200

-0.06(-0.111%)1D

AKRO Relative Valuation

AKRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AKRO is overvalued; if below, it's undervalued.

Historical Valuation

Akero Therapeutics Inc (AKRO) is now in the Fair zone, suggesting that its current forward PS ratio of 54.20 is considered Fairly compared with the five-year average of -8.99. The fair price of Akero Therapeutics Inc (AKRO) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：54.20

Fair

-13.88

Trailing

Forward

-9.27

EV/EBITDA

Akero Therapeutics Inc. (AKRO) has a current EV/EBITDA of -9.27. The 5-year average EV/EBITDA is -6.26. The thresholds are as follows: Strongly Undervalued below -13.76, Undervalued between -13.76 and -10.01, Fairly Valued between -2.51 and -10.01, Overvalued between -2.51 and 1.24, and Strongly Overvalued above 1.24. The current Forward EV/EBITDA of -9.27 falls within the Historic Trend Line -Fairly Valued range.

-9.43

EV/EBIT

Akero Therapeutics Inc. (AKRO) has a current EV/EBIT of -9.43. The 5-year average EV/EBIT is -6.24. The thresholds are as follows: Strongly Undervalued below -13.75, Undervalued between -13.75 and -9.99, Fairly Valued between -2.48 and -9.99, Overvalued between -2.48 and 1.27, and Strongly Overvalued above 1.27. The current Forward EV/EBIT of -9.43 falls within the Historic Trend Line -Fairly Valued range.

54.20

Akero Therapeutics Inc. (AKRO) has a current PS of 54.20. The 5-year average PS is 0.26. The thresholds are as follows: Strongly Undervalued below -7.22, Undervalued between -7.22 and -3.48, Fairly Valued between 4.00 and -3.48, Overvalued between 4.00 and 7.74, and Strongly Overvalued above 7.74. The current Forward PS of 54.20 falls within the Strongly Overvalued range.

-15.43

P/OCF

Akero Therapeutics Inc. (AKRO) has a current P/OCF of -15.43. The 5-year average P/OCF is -11.09. The thresholds are as follows: Strongly Undervalued below -20.72, Undervalued between -20.72 and -15.91, Fairly Valued between -6.28 and -15.91, Overvalued between -6.28 and -1.47, and Strongly Overvalued above -1.47. The current Forward P/OCF of -15.43 falls within the Historic Trend Line -Fairly Valued range.

-15.43

P/FCF

Akero Therapeutics Inc. (AKRO) has a current P/FCF of -15.43. The 5-year average P/FCF is -11.58. The thresholds are as follows: Strongly Undervalued below -24.47, Undervalued between -24.47 and -18.03, Fairly Valued between -5.13 and -18.03, Overvalued between -5.13 and 1.31, and Strongly Overvalued above 1.31. The current Forward P/FCF of -15.43 falls within the Historic Trend Line -Fairly Valued range.

Akero Therapeutics Inc (AKRO) has a current Price-to-Book (P/B) ratio of 4.22. Compared to its 3-year average P/B ratio of 3.77 , the current P/B ratio is approximately 11.86% higher. Relative to its 5-year average P/B ratio of 3.75, the current P/B ratio is about 12.75% higher. Akero Therapeutics Inc (AKRO) has a Forward Free Cash Flow (FCF) yield of approximately -5.83%. Compared to its 3-year average FCF yield of -7.76%, the current FCF yield is approximately -24.87% lower. Relative to its 5-year average FCF yield of -9.37% , the current FCF yield is about -37.73% lower.

4.22

P/B

Median3y

3.77

Median5y

3.75

-5.83

FCF Yield

Median3y

-7.76

Median5y

-9.37

Competitors Valuation Multiple

The average P/S ratio for AKRO's competitors is 75.39, providing a benchmark for relative valuation. Akero Therapeutics Inc Corp (AKRO) exhibits a P/S ratio of 54.20, which is -28.11% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AKRO.O

Akero Therapeutics Inc

Praxis Precision Medicines Inc

NewAmsterdam Pharma Company NV

Protagonist Therapeutics Inc

Viking Therapeutics Inc

38.08

4.30B

Performance Decomposition

Market capitalization of AKRO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of AKRO in the past 1 year is driven by Unknown.